Trial Profile

An Observational Multi Center Study to Evaluate Real World Treatment Outcomes of Durvalumab Based Regimens in Hepatobiliary Cancers

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 11 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cisplatin (Primary) ; Durvalumab (Primary) ; Gemcitabine (Primary) ; Tremelimumab (Primary)
Indications Biliary cancer; Liver cancer
Focus Therapeutic Use
Acronyms LIVER-R
Sponsors AstraZeneca

Most Recent Events

25 Nov 2024 Planned End Date changed from 13 Dec 2029 to 30 Dec 2030.
25 Nov 2024 Planned primary completion date changed from 13 Dec 2029 to 30 Dec 2030.
25 Mar 2024 Planned number of patients changed from 2490 to 4490.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com